Knepel W, Götz D, Fahrenholz F
Neuroendocrinology. 1986;44(3):390-6. doi: 10.1159/000124674.
We readdressed the question of whether or not rat adenohypophyseal vasopressin receptors have a ligand selectivity which is similar to that of the V1 subtype of vasopressin receptors. Vasopressin analogues substituted in positions 7 and 1 were used. By incubating rat anterior pituitary quarters or by perifusing rat isolated anterior pituitary cells, the effect of the vasopressin analogues on the release of beta-endorphin-like or adrenocorticotropin-like immunoreactivity was examined. The replacement of the proline residue in position 7 by sarcosine or N-methyl-alanine did not change the maximum effect reached but increased the EC50 values 20- or 5-fold, respectively, when compared with arginine vasopressin. This decrease in beta-endorphin-releasing activity was no longer observed after additional removal of the alpha-amino group of cysteine in position 1. Since these substitutions are known to drastically reduce vasopressor activity, these data suggest that the beta-endorphin-releasing activity of vasopressin can be dissociated from its V1 receptor activity. Vasopressin analogues substituted in position 7 and with deaminopenicillamine or beta-mercapto-beta,beta-cyclopentamethylenepropionic acid in position 1 were found to be weak antagonists of the beta-endorphin-releasing activity of vasopressin. Since these analogues are potent antagonists at the V1 receptor, these data suggest that the deaminopenicillamine and, more so, the beta-mercapto-beta,beta-cyclopentamethylenepropionic acid residues in position 1 of vasopressin are strong 'binding elements' at the V1 vasopressin receptor but weak 'binding elements' at the adenohypophyseal vasopressin receptor.(ABSTRACT TRUNCATED AT 250 WORDS)
我们重新探讨了大鼠腺垂体血管加压素受体是否具有与血管加压素受体V1亚型相似的配体选择性这一问题。使用了在第7位和第1位进行取代的血管加压素类似物。通过孵育大鼠垂体前叶组织块或灌注大鼠分离的垂体前叶细胞,检测了血管加压素类似物对β-内啡肽样或促肾上腺皮质激素样免疫反应性释放的影响。与精氨酸血管加压素相比,将第7位的脯氨酸残基替换为肌氨酸或N-甲基丙氨酸不会改变所达到的最大效应,但分别使半数有效浓度(EC50)值增加了20倍或5倍。在进一步去除第1位半胱氨酸的α-氨基后,不再观察到β-内啡肽释放活性的这种降低。由于已知这些取代会大幅降低血管升压活性,这些数据表明血管加压素的β-内啡肽释放活性可与其V1受体活性分离。发现第7位进行取代且第1位为脱氨青霉胺或β-巯基-β,β-环戊亚甲基丙酸的血管加压素类似物是血管加压素β-内啡肽释放活性的弱拮抗剂。由于这些类似物是V1受体的强效拮抗剂,这些数据表明血管加压素第1位的脱氨青霉胺,更确切地说是β-巯基-β,β-环戊亚甲基丙酸残基是V1血管加压素受体上的强“结合元件”,但在腺垂体血管加压素受体上是弱“结合元件”。(摘要截短至250字)